## Background: It has been suggested that cyclin-dependent kinase inhibitors (cdkis), including p16 and p15, are tumor suppressor genes. alterations of cdkis have been found in most types of cancer. however, little is known about the status of p16 and p15 genes, including methylation of the promote
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas
โ Scribed by Rossella Elisei; Masaaki Shiohara; H. Phillip Koeffler; James A. Fagin
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 186 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
D-type cyclins, in association with the cyclin-dependent kinases cdk4 and cdk6, promote progression through the g1 phase of the cell cycle. cdk activity is modulated by inhibitors such as p15ink4b and p16ink4a. loss of function of p15ink4b and p16ink4a (multiple tumor suppressor-i and cdk4 inhibitor) determines impairment in the control of the cell cycle and contributes to the transformation of several cell types.
Methods:
The authors examined 20 thyroid neoplasms (12 papillary carcinomas and 8 follicular adenomas) and 4 human thyroid carcinoma cell lines for gene mutations and epigenetic modifications of the p15ink4b and p16ink4a genes by southern blot analysis, single strand conformation polymorphism, and a polymerase chain reaction-based methylation assay.
Results:
Abnormalities of p16 were found in the four cell lines studied. in follicular carcinoma (wro) cells, both the p15 and p16 genes were homozygously deleted. undifferentiated carcinoma (fro) cells had a nonsense point mutation at codon 72 (cga-tga, arg-stop) of p16, whereas the poorly differentiated papillary carcinoma (npa) line harbored a point mutation at the exon 1-intron 1 boundary that altered the donor splicing site and caused an aberrantly spliced form of p16ink4a. furthermore, p16 allelic loss was evident in the dna of both fro and npa cells. finally, p16 expression was absent in the aro cell line, likely due to a de novo methylation of exon 1 of p16ink4a. regarding the primary thyroid tumors, a missense point mutation at codon 91 was found in 1 of 12 papillary thyroid carcinomas (gcc-gtc, ala-val). no mutations were found in follicular adenomas. however, in 6 of 20 primary tumors there was hypermethylation at exon 1 of p16.
Conclusions:
The high prevalence of p15 and p16 mutations in the cell lines described suggests involvement of these genes in immortalization in vitro. the p16 defects may have preexisted in a small subclone of the primary tumor that were selected for in vitro. alternatively, p16 mutations may have arisen de novo during cell culture. mutations of p15ink4b and p16ink4a do not appear to be critical events in the development of follicular adenomas or papillary carcinomas. however, de novo methylation of the 5' cpg island of p16 is common in primary tumors, indicating that the function of this gene may be lost as an epigenetic event during disease progression.
๐ SIMILAR VOLUMES
## Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16 INK4A and/or up-regulation of cyclin D1. In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohisto
The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alte
The 9p21-23 chromosome region harbors a number of known and putative tumor-suppressor genes (TSGs). The best characterized gene in this area is p16 INK4A (CDKN2A). Alterations of its product have been observed in various malignancies, including non-small-cell lung carcinomas (NSCLCs). We earlier inv